It is reported that 9.2% of Canadians will experience PTSD in their lifetime.1 In honour of PTSD Awareness Day, Aurora recognizes those who are suffering from this illness.
What is PTSD?
PTSD, or Post-Traumatic Stress disorder can be characterized by intrusive distressing memories, persistent negative thoughts, avoidance of stressful triggers and persistent symptoms of hyperarousal (irritability, feeling jumpy, difficulty sleeping, etc).2 PTSD can develop from experiencing, witnessing, or learning about a traumatic event.3
Women are reported to be twice as likely to develop PTSD in comparison to men.4 PTSD is also more prevalent among first-responders, and those exposed to specific traumas, such as combat exposure or interpersonal violence.5,6 Currently, there remains a lack of effective treatment for PTSD, with standardized treatment resulting in only 20-30% of individuals showing full recovery.7
What Science Says About CBD and PTSD
Studies have shown the usefulness of CBD in treating PTSD. A retrospective case series published in The Journal of Alternative and Complementary Medicine found that CBD significantly decreased PTSD symptom severity in 91% of patients.8
And in a double-blind placebo-controlled study examining the reduction of fear-associated memories in healthy volunteers, CBD inhaled before or after extinction training of fear memories resulted in decreased recall of these fear-associated memories later on.9 Emerging evidence in pre-clinical research also supports the potential usefulness of CBD in treating symptoms of PTSD.10,11
Better Days with Aurora ®
Aurora® carries a comprehensive selection of CBD products, including dried flower, softgels, vaporizers, edibles and more. To browse, please visit this link.
We hope this information has been helpful to you in making the most well-informed decisions for your health and wellness.
- Dückers MLA, Alisic E, Brewin CR. A vulnerability paradox in the cross-national prevalence of post-traumatic stress disorder. British Journal of Psychiatry. 2016;209(4):300-305.
- American Psychological Association. Guideline Development Panel for the Treatment of Posttraumatic Stress Disorder in Adults. February 24, 2017. Accessed May 16, 2021. https://www.apa.org/ptsd-guideline
- National Institute of Mental Health. Post-Traumatic Stress Disorder. 2020. Accessed May 16, 2021. https://www.nimh.nih.gov/health/publications/post-traumatic-stress-disorder-ptsd/
- Ozer EJ, Best SR, Lipsey TL, Weiss DS. Predictors of posttraumatic stress disorder and symptoms in adults: A meta-analysis. Psychological Bulletin. 2003;129(1):52-73.
- Breslau N, Chilcoat HD, Kessler RC, Davis GC. Previous exposure to trauma and PTSD effects of subsequent trauma: Results from the Detroit area survey of trauma. American Journal of Psychiatry. 1999;156(6):902-907.
- Cougle JR, Resnick H, Kilpatrick DG. Does prior exposure to interpersonal violence increase risk of PTSD following subsequent exposure? Behaviour Research and Therapy. 2009;47(12):1012-1017.
- Berger W, Mendlowicz M v., Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009;33(2):169-180.
- Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. The Journal of Alternative and Complementary Medicine. 2019;25(4):392-397.
- Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology, 226(4), 781-792
- Campos AC, Ferreira FR, Guimarães FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors. Journal of Psychiatric Research. 2012;46(11):1501-1510.
- Uribe-Marĩo A, Francisco A, Castiblanco-Urbina MA, et al. Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology. 2012;37(2):412-421.